Publications by authors named "Masaki Setoguchi"

Claim this Profile
P
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Dimpy Koul, Shuzhen Wang, Shaofang Wu, Norihiko Saito, Siyuan Zheng, Masaki Setoguchi

Oncotarget· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
Yoshihiro Shibata, Katsuji Kagechika, Masahiro Ota, Mitsuhiro Yamaguchi, Masaki Setoguchi

Chem Pharm Bull (Tokyo)· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba

Bioorg Med Chem· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A concise synthesis of a very late antigen-4 antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid via reductive etherification.
Jun Chiba, Fumihito Muro, Masaki Setoguchi, Nobuo Machinaga

Chem Pharm Bull (Tokyo)· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba

Bioorg Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
Fumihito Muro, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba, Masaki Setoguchi

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Masaki Setoguchi

Bioorg Med Chem· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Masaki Setoguchi

Bioorg Med Chem· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis